Form 8-K - Current report:
SEC Accession No. 0000950170-25-071839
Filing Date
2025-05-15
Accepted
2025-05-15 06:02:09
Documents
13
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aura-20250513.htm   iXBRL 8-K 54921
2 EX-99.1 aura-ex99_1.htm EX-99.1 225857
3 GRAPHIC img28679202_0.jpg GRAPHIC 8396
  Complete submission text file 0000950170-25-071839.txt   428966

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aura-20250513.xsd EX-101.SCH 26009
15 EXTRACTED XBRL INSTANCE DOCUMENT aura-20250513_htm.xml XML 4925
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 (617)500-8864
Aura Biosciences, Inc. (Filer) CIK: 0001501796 (see all company filings)

EIN.: 320271970 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40971 | Film No.: 25948338
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)